Amended Notification That Annual Report Will Be Submitted Late (nt 10-k/a)
May 14 2020 - 1:19PM
Edgar (US Regulatory)
|
|
|
OMB APPROVAL
|
|
|
|
OMB Number:
3235-0058
|
|
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
|
Expires:
February 28, 2022
|
Estimated
average burden
|
|
|
|
hours per
response.......2.50
|
|
|
|
|
|
FORM
12b-25
|
SEC FILE NUMBER
|
|
0-28666
|
|
|
|
|
|
|
|
CUSIP NUMBER
|
|
NOTIFICATION
OF LATE FILING
|
024600
|
(Check one):
|
☑
|
Form
10-K
|
☐
|
Form
20-F
|
☐
|
Form
11-K
|
☐
|
Form
10-Q
|
☐
|
Form
10-D
|
☐
|
Form
N-SAR
|
☐
|
Form
N-CSR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For Period Ended:
December 31,
2019
|
|
|
|
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 10-K
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 20-F
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 11-K
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 10-Q
|
|
|
|
|
|
|
☐
|
Transition
Report on Form N-SAR
|
|
|
|
|
|
|
|
|
For the Transition Period
Ended:
|
|
|
Nothing
in this form shall be construed to imply that the Commission has
verified any information contained herein.
|
If the notification
relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
|
|
|
PART
I — REGISTRANT INFORMATION
|
American
Bio Medica Corporation
|
|
Full Name of
Registrant
|
|
Not
Applicable
|
|
Former Name if
Applicable
|
|
122 Smith Road
|
|
Address of
Principal Executive Office (Street
and Number)
|
|
Kinderhook, New York 12106
|
|
City, State and Zip
Code
|
PART II —
RULES 12b-25(b) AND (c)
If the subject report could not be filed
without unreasonable effort or expense and the registrant seeks
relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
|
(a)
|
The reason
described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense
|
|
|
|
☒
|
(b)
|
The subject annual
report, semi-annual report, transition report on Form 10-K, Form
20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will
be filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report or transition
report on Form 10-Q or subject distribution report on Form 10-D, or
portion thereof, will be filed on or before the fifth calendar day
following the prescribed due date; and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
|
|
|
|
PART
III – NARRATIVE
State below in
reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
10-D, N-SAR, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
(Attach extra
Sheets if Needed)
The registrant was
unable to timely file its requisite annual report on Form 10-K for
the fiscal year ended December 31, 2019 by the prescribed due date
of March 31, 2020. The registrant continues to be impacted by
government imposed restrictions due to the outbreak of corornavirus
(COVID-19). The registrant originally believed it would be able to
complete and file its Form 10-K for the year ended December 31,
2019 by May 14, 2020, however, without unreasonable effort and
expense, the Registrant needs additional time to finalize the
financial statements, certain disclosures and analyses that are
included in the Form 10-K. In accordance with Rule 12b-25
promulgated under the Securities and Exchance Act of 1934, as
amended, the Registrant intends to file its Form 10-K on or prior
to May 29, 2020.
PART
IV — OTHER INFORMATION
|
(1)
|
Name and telephone
number of person to contact in regard to this
notification
|
|
|
Melissa A. Waterhouse
|
|
(518)
|
|
758-8158
|
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
|
(2)
|
Have all other
periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such
report(s) been filed? If answer is no, identify
report(s).
|
Yes
|
☑
|
No
|
☐
|
|
|
|
|
(3)
|
Is it anticipated
that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by
the earnings statements to be included in the subject report or
portion thereof?
|
Yes
|
☐
|
No
|
☑
|
|
|
|
If so, attach an
explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
|
|
|
|
American
Bio Medica Corporation
|
|
(Name of Registrant
as Specified in Charter)
|
|
has caused this
notification to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
|
By:
|
/s/ Melissa A.
Waterhouse
|
|
|
|
|
Name: Melissa A.
Waterhouse
|
|
|
|
|
Title: Chief Executive
Officer/ Principal Financial Officer
|
3
American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From Aug 2024 to Sep 2024
American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From Sep 2023 to Sep 2024